NCT00193414

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC. This study will serve to define the role of next generation agents in a new combination regimen in the treatment of advanced NSCLC. This combination regimen may ultimately be important in further expanding treatment options for patients while improving survival, quality of life, and symptom control compared with platinum-based combination regimens - and with acceptable toxicity.

Detailed description

Upon determination of eligibility, patients will be receive: * Pemetrexed + Gemcitabine

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Pemetrexed	500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
DRUG	Gemcitabine	1500mg/m2, 30min IV

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-12-01
• Completion: 2009-08-01
• First posted: 2005-09-19
• Last updated: 2022-03-03
• Results posted: 2012-11-13

Locations

1 site across 1 country: United States